Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.Ronald G. Steis, John Edward McKnight, John W. Smith et al.|Journal of Clinical Oncology|1990Cited by 106
Intraperitoneal Lymphokine-Activated Killer Cell/Interleukin-2 Therapy in Patients With Intra- abdominal Cancer: Immunologic ConsiderationsWalter J. Urba, Dan L. Longo, Jeffrey W. Clark et al.|JNCI Journal of the National Cancer Institute|1989Cited by 51